SEQUENCE LISTING

<110> Sapreme Technologies B.V.
Charité - UNIVERSITÄTSMEDIZIN BERLIN

<120> ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW

<130> P6089257PCT

<140> PCT/EP2019/084180
<141> 2019-12-09

<160> 12

<170> PatentIn version 3.5

<210> 1
<211> 16
<212> DNA
<213> Antisense BNA (HSP27) oligo nucleic acid sequence

<400> 1
ggcacagcca gtggcg 16

<210> 2
<211> 18
<212> DNA
<213> UBC primer forward sequence

<400> 2
cagccgggat ttgggtcg 18

<210> 3
<211> 23
<212> DNA
<213> UBC primer reverse sequence

<400> 3
cacgaagatc tgcattgtca agt 23

<210> 4
<211> 20
<212> DNA
<213> GUSB primer forward sequence

<400> 4
tgcgtaggga caagaaccac 20

<210> 5
<211> 20

<212> DNA
<213> GUSB primer reverse sequence

<400> 5
gggaggggtc caaggatttg 20

<210> 6
<211> 20
<212> DNA
<213> IMMT primer forward sequence

<400> 6
aacccacacc tgcactttca 20

<210> 7
<211> 20
<212> DNA
<213> IMMT primer reverse sequence

<400> 7
ttttcctgtt gtgcaaggcg 20

<210> 8
<211> 20
<212> DNA
<213> EIF2S2 primer forward sequence

<400> 8
ccacaagtcg tccgagtagg 20

<210> 9
<211> 20
<212> DNA
<213> EIF2S2 primer reverse sequence

<400> 9
ggagatgttt gggctgacga 20

<210> 10
<211> 20
<212> DNA
<213> HSP27 primer forward sequence

<400> 10
gcagtccaac gagatcacca 20

<210> 11
<211> 20

<212> DNA
<213> HSP27 primer reverse sequence

<400> 11
taaggcttta cttggcggca 20

<210> 12
<211> 18
<212> PRT
<213> Customized peptide

<400> 12

Ser Glu Ser Asp Asp Ala Met Phe Cys Asp Ala Met Asp Glu Ser Asp
1 5 10 15

Ser Lys